Cargando…

Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson’s disease

BACKGROUND: Parkinson’s disease (PD) is a progressive neurodegenerative disease with characteristic pathological abnormalities, including the loss of dopaminergic (DA) neurons, a dopamine-depleted striatum, and microglial activation. Lipid accumulation exhibits a close relationship with these pathol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Jiewen, Peng, Guoyou, Tang, Yuting, Li, Shiyin, Liu, Zengfu, Zheng, Jiayun, Wang, Yunxin, Liu, Hanqun, Wei, Lijian, Su, Yilin, Lin, Yuwan, Dai, Wei, Zhang, Zhiling, Chen, Xiang, Ding, Liuyan, Guo, Wenyuan, Zhu, Xiaoqin, Xu, Pingyi, Mo, Mingshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895836/ https://www.ncbi.nlm.nih.gov/pubmed/36742201 http://dx.doi.org/10.3389/fnagi.2022.1077738

Ejemplares similares

Soluble Triggering Receptor Expressed on Myeloid Cells 2 From Cerebrospinal Fluid in Sleep Disorders Related to Parkinson’s Disease
por: Mo, Mingshu, et al.
Publicado: (2021)

Lipid Metabolism Disorder in Cerebrospinal Fluid Related to Parkinson’s Disease
por: Qiu, Jiewen, et al.
Publicado: (2023)

Association of LAG3 genetic variation with an increased risk of PD in Chinese female population
por: Guo, Wenyuan, et al.
Publicado: (2019)

Bone-Derived Factors as Potential Biomarkers for Parkinson’s Disease
por: Lin, Yuwan, et al.
Publicado: (2021)

CHCHD2 Thr61Ile mutation impairs F1F0-ATPase assembly in in vitro and in vivo models of Parkinson’s disease
por: Chen, Xiang, et al.
Publicado: (2023)

Berberine Protects Against NLRP3 Inflammasome via Ameliorating Autophagic Impairment in MPTP-Induced Parkinson’s Disease Model
por: Huang, Shuxuan, et al.
Publicado: (2021)

Parkinson’s disease in a patient with GBA and LRRK2 covariants after acute hypoxic insult: a case report
por: Tang, Yuting, et al.
Publicado: (2023)

CHCHD2 maintains mitochondrial contact site and cristae organizing system stability and protects against mitochondrial dysfunction in an experimental model of Parkinson's disease
por: Lu, Lin, et al.
Publicado: (2022)

A case of congenital afibrinogenemia with multiple thrombotic and hemorrhagic disorders
por: Wei, Lijian, et al.
Publicado: (2022)

Functional validation of a human GLUD2 variant in a murine model of Parkinson’s disease
por: Zhang, Wenlong, et al.
Publicado: (2020)

Wnt3a protects SH-SY5Y cells against 6-hydroxydopamine toxicity by restoration of mitochondria function
por: Wei, Lei, et al.
Publicado: (2015)

A Novel Hydrogen Sulfide Donor Reduces Pilocarpine-Induced Status Epilepticus and Regulates Microglial Inflammatory Profile
por: Liu, Zhongrui, et al.
Publicado: (2021)

CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes
por: Zhang, Wenlong, et al.
Publicado: (2020)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Parkinson’s Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
por: Silva da Fonsêca, Victor, et al.
Publicado: (2023)

The dosage of curcumin to alleviate movement symptoms in a 6-hydroxydopamine-induced Parkinson's disease rat model
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
por: Liu, Lan-Xiang, et al.
Publicado: (2018)

NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson’s disease
por: Cheng, Li, et al.
Publicado: (2018)

Intranasal delivery of mitochondria for treatment of Parkinson’s Disease model rats lesioned with 6-hydroxydopamine
por: Chang, Jui-Chih, et al.
Publicado: (2021)

The biomarkers of immune dysregulation and inflammation response in Parkinson disease
por: Chen, Li, et al.
Publicado: (2016)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease
por: Pišlar, Anja, et al.
Publicado: (2018)

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)

Trojan Horse Delivery of 4,4′‐Dimethoxychalcone for Parkinsonian Neuroprotection
por: Zhang, Wenlong, et al.
Publicado: (2021)

Ghrelin alleviates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells
por: He, Xin, et al.
Publicado: (2021)

Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease
por: Stayte, Sandy, et al.
Publicado: (2015)

Metabolomics and biochemical alterations caused by pleiotrophin in the 6-hydroxydopamine mouse model of Parkinson’s disease
por: Gramage, Esther, et al.
Publicado: (2022)

Wnt1 Promotes EAAT2 Expression and Mediates the Protective Effects of Astrocytes on Dopaminergic Cells in Parkinson's Disease
por: Wei, Lei, et al.
Publicado: (2019)

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model
por: Kambey, Piniel Alphayo, et al.
Publicado: (2023)

Reduced regional activity and functional connectivity within sensorimotor network in Parkinson’s patients with restless legs syndrome
por: Li, Zhe, et al.
Publicado: (2019)

Time-course behavioral features are correlated with Parkinson's disease-associated pathology in a 6-hydroxydopamine hemiparkinsonian rat model
por: Su, Rui-Jun, et al.
Publicado: (2018)

Cognitive-Enhancing Effect of Quercetin in a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Sriraksa, Napatr, et al.
Publicado: (2012)

Treadmill exercise alleviates short-term memory impairment in 6-hydroxydopamine-induced Parkinson’s rats
por: Cho, Han-Sam, et al.
Publicado: (2013)

Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson’s Disease
por: Haas, Stefan Jean-Pierre, et al.
Publicado: (2016)

Impaired Voluntary Wheel Running Behavior in the Unilateral 6-Hydroxydopamine Rat Model of Parkinson's Disease
por: Pan, Qi, et al.
Publicado: (2015)

Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease
por: De Jesús-Cortés, Héctor, et al.
Publicado: (2015)

Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease
por: Westphal, Robert, et al.
Publicado: (2017)

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020)

Transcriptome profiling of five brain regions in a 6‐hydroxydopamine rat model of Parkinson’s disease
por: Lyu, Ying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k4feg2l4f5p5bmsuar31lbj1ls